Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ: DYN )

23.97 +0.06 (+0.25%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Looking Into Dyne Therapeutics's Recent Short Interest
Via Benzinga
Peering Into Dyne Therapeutics's Recent Short Interest
Via Benzinga
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
Via Benzinga
Exposures Fossil Fuels
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... 
Via Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results. 
Via Investor's Business Daily
Nasdaq Dips Over 2%; US Construction Spending Falls In July
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates
Via Benzinga
Topics Stocks
Exposures US Equities
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?
Find out the significance of the 
Via Talk Markets
Topics Stocks
Exposures US Equities
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?
A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to... 
Via Benzinga
Topics Economy
Exposures Interest Rates
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024
DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
Chart Of The Day: Dyne Therapeutics - Deeply Discounted
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United... 
Via Talk Markets
Casey's Reports Upbeat Earnings, Joins Avidity Biosciences, Rentokil Initial And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Soft Inflation Data Boosts Small Caps, Real Estate, Regional Banks; Traders Anticipate Fed Rate Cuts As Stocks React
U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cut in September. 
Via Benzinga
Topics Economy
Exposures Interest Rates
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate 
Via InvestorPlace
Modine Manufacturing Posts Mixed Q4 Results, Joins Viasat, Lululemon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Is Dyne Therapeutics Stock Soaring On Monday?
Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne muscular dystrophy. Improvements in splicing correction, myotonia, muscle... 
Via Benzinga
Tech Surge Boosts Nasdaq To Record Highs
The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Dyne Therapeutics, With A 108% Run This Year, Just Catapulted Again
Dyne Therapeutics is looking to take on Sarepta Therapeutics in DMD. 
Via Investor's Business Daily
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a great way to start the trading week and we have all of the hottest news worth reading about on Monday! 
Via InvestorPlace
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Cantor Fitzgerald initiates coverage on Avidity Biosciences highlighting a robust pipeline led by del-desiran, a promising treatment for Myotonic dystrophy type 1. With strong management, proven... 
Via Benzinga
Chardan Capital Maintains Buy Rating for Dyne Therapeutics: Here's What You Need To Know
Via Benzinga
Piper Sandler Maintains Overweight Rating for Dyne Therapeutics: Here's What You Need To Know
Via Benzinga
DYN Stock Earnings: Dyne Therapeutics Misses EPS for Q4 2023
DYN stock results show that Dyne Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.